ERBB2 and breast cancer: However, we did not observed any statistical significance in the PFS and OS of patients that were treated with pyrotinib plus capecitabine in different treatment lines, which suggested that pyrotinib plus capecitabine could be beneficial for HER2+ BC patients from any line therapy.